Sign Out
Monotherapy: TENELIA is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Combination therapy: TENELIA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, sulfonylureas, PPAR agonist (e.g., thiazolidinediones), rapid insulin secretagogues, alpha-glucosidase inhibitors, sodium glucose co-transporter 2 inhibitor, or insulin when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
